Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 3Phase 2/3 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Carcinoma, Hepatocellular 5Stomach Neoplasms 4Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Osteosarcoma 1Neoplasm Metastasis 1Immunotherapy Gastrict Cancer 1Esophageal Neoplasms 1Adenocarcinoma 1

Interventions

Gemcitabine 5Capecitabine 4pembrolizumab 3Fluorouracil 3Cisplatin 3vinflunine 2enzalutamide 2cabazitaxel 2abiraterone 2Ipilimumab 2Haloperidol 2Androgen Antagonists 2vedolizumab 1trifluridine tipiracil drug combination 1relugolix 1racemetyrosine 1nimotuzumab 1nilutamide 1lanreotide 1histrelin 1futibatinib 1exemestane 1dexamethasone acetate 1dexamethasone 21-phosphate 1bicalutamide 1beta-Glucans 1auricularum 1atezolizumab 1apatinib 1apalutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Neoplasm Metastasis × apatinib × Clear all
NCT02711007 2018-04-23

Apatinib for Advanced Osteosarcoma After Failure of Standard Multimodal Therapy

Peking University People's Hospital

Phase 2/3 Completed
37 enrolled
Sarcoma

Neoplasm Metastasis, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡